MK-434 explained

MK-434 is a 5α-reductase inhibitor which was under development in the 1990s by Merck & Co for the treatment of a variety of androgen-dependent conditions including benign prostatic hyperplasia, prostate cancer, pattern hair loss, excessive hair growth, acne, and seborrhea but was never marketed.^{[1] [2] [3]} It acts as a selective inhibitor of 5α-reductase type 2.^[4] The drug has been found to decrease circulating dihydrotestosterone levels by a maximum of approximately 50% in men. MK-434 is a synthetic 4-azasteroid and is structurally related to other 5α-reductase inhibitors like finasteride.

See also

• List of 5α-reductase inhibitors

External links

• MK-434 - AdisInsight

Notes and References

1. Web site: MK 434 - AdisInsight.
2. Chen W, Zouboulis CC, Orfanos CE . The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders . Dermatology (Basel) . 193 . 3 . 177–84 . 1996 . 8944337 . 10.1159/000246242 .
3. Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, Ng J, De Schepper PJ . Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects . Eur. J. Clin. Pharmacol. . 46 . 2 . 123–6 . 1994 . 8039530 . 10.1007/bf00199874. 22756609 .
4. Cooke GM, Pothier F, Murphy BD . The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity . J. Steroid Biochem. Mol. Biol. . 60 . 5–6 . 353–9 . March 1997 . 9219928 . 10.1016/s0960-0760(96)00223-3. 25760027 .